Provectus Pharmaceuticals, Inc. received orphan drug designation by the U.S. Food and Drug Administration (FDA) for Rose Bengal, the active ingredient in oncology drug PV-10, for the treatment of hepatocellular carcinoma (HCC)– the most common form of liver cancer.
Debiopharm Group and Aurigene Discovery Technologies signed an agreement concerning the development and commercialization of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.
Cancer drug developer Celldex Therapeutics Inc. reported a larger first-quarter loss, saying its revenue and investment income decreased. Celldex lost $10.1 million, or 31 cents per share.
Par Pharmaceutical posted a first-quarter loss following a quarter in which the generic drug developer saw sales of a key drug slide and also a hefty legal charge.
Johnson & Johnson and other makers of cold and fever medications said that they will discontinue infant drops of medicines containing acetaminophen in an effort to avoid confusion that can lead to dangerous overdoses.
The Supreme Court will hear a Canadian drug maker's challenge of the Viagra patent held by pharmaceutical giant Pfizer. The high court granted the leave to appeal that was being sought by Teva Canada.
Eli Lilly and Company announced results from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer.
Algeta has entered a research, development, and commercialization agreement with Affibody to develop tumor-targeting alpha-pharmaceuticals based on thorium-227.
Argos Therapeutics announced that an immunotherapy platform based on recombinant human soluble CD83 demonstrated significant promise for renal and heart transplantation.
Cancer Research UK scientists discovered tumors can recruit part of the body’s defense system to protect them from the effect of a drug designed to block the supply of blood to the tumor.
The drug discovery and development community is faced with an immense challenge, as it moves to bring novel analgesic medicines, with an improvement in efficacy, responder rate, and safety to the market.
Nycomed and Almirall have entered a co-branding agreement for the commercialization in Spain of Roflumilast, a once-daily tablet for patients with chronic obstructive pulmonary disease (COPD).
Tuberculosis (TB) is widely considered a public health concern and its treatment a public sector responsibility; however, the private sector aspect for its treatment is ignored.
A study, “The Telomerase Activator TA-65 elongates short telomeres and increases healthspan of adult/old mice without increasing cancer incidence” describes TA-65’s mechanism of action and organismal response.